

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BAMBOOS HEALTH CARE HOLDINGS LIMITED

百本醫護控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2293)

SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED 30 JUNE 2024

Reference is made to the annual report for the year ended 30 June 2024 (the “**2024 Annual Report**”). Save as disclosed in this announcement, the supplementary information provided herein does not affect other information contained in the 2024 Annual Report. Unless otherwise defined or the context requires otherwise, capitalised terms used herein shall have the same meanings as those defined in the 2024 Annual Report.

REMUNERATION COMMITTEE OF THE BOARD (THE “REMUNERATION COMMITTEE”)

The following sets forth the supplemental information to the 2024 Annual Report on the Share Award Scheme pursuant to Rule 17.03(F), 17.06(B)(7) and 17.06(B)(8) of the Listing Rules.

The primary objectives and duties of the Remuneration Committee are set forth in its terms of reference adopted in compliance with the requirements under the CG Code, which include, *inter alia*, (i) making recommendations to the Board on the remuneration policy and structure for all the Directors and the senior management of the Company and on the establishment of a set of formal and transparent procedures for developing its remuneration policy; (ii) reviewing and approving the management’s remuneration proposals with reference to the Board’s corporate goals and objectives; and (iii) to review and/or approve matters relating to share schemes under Chapter 17 of the Listing Rules.

Summary of matters relating to the Share Award Scheme reviewed by the Remuneration Committee

During the year ended 30 June 2024, 2,460,000 share awards have been granted to 21 selected employees who are not connected persons of the Group with the vesting periods and performance targets as set out in the 2024 Annual Report. There were no grants of share awards with a shorter vesting period as set out in Rule 17.03F of the Listing Rules. Details of the clawback mechanism for the Company to recover or withhold any awards granted are set out in the announcement of the Company dated 1 December 2023.

In respect of the share awards granted during the year ended 30 June 2024, the Remuneration Committee considers that the Share Award Scheme is intended to (i) recognise and reward the contribution of certain eligible participants to the growth and development of the Group and to give incentives to them in order to retain them for the continual operation and development of the Group; and (ii) attract suitable personnel for further development of the Group. In addition, the Remuneration Committee considers that the share awards align with the purpose of the Share Award Scheme and align the awardees' interests with those of the Company and the Shareholders in that:

- (a) the awardees are eligible participants under the Share Award Scheme who would contribute directly to the overall business performance and sustainable development of the Group;
- (b) the granting of share awards to the awardees is a recognition for their past contributions to the Group; and
- (c) the share awards are subject to the terms of the Share Award Scheme which provides for circumstances under which the share awards may lapse.

By order of the Board
Bamboos Health Care Holdings Limited
Hai Hiu Chu
Chairman and executive Director

Hong Kong, 11 June 2025

As at the date of this announcement, the executive Directors are Ms. Hai Hiu Chu and Mr. Cheng Sau Kong; and the independent non-executive Directors are Dr. Chan Kai Yue Jason, Mr. Wong Kon Man Jason and Mr. Lam Kwok Ming.